日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

一线帕博利珠单抗治疗微卫星稳定性状态不一致的子宫内膜腺癌：病例报告及叙述性综述

期刊:American Journal of Case Reports
影响因子:0.7
doi:10.12659/AJCR.939448
Grant, Christopher R; Chiao, Elaine J; Arter, Zhaohui L; Johnson, Cary; Tran, Truc; Dayyani, Farshid; Tewari, Krishnasu; Vilchez, Valery; Carmichael, Joseph; Cho, May
肿瘤免疫
肿瘤
发表日期：2023
文献求助 收藏

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study

一项针对局限于盆腔的IB2、IIA、IIB、IIIB和IVA期宫颈癌患者的III期随机试验，比较了每周顺铂联合放疗与顺铂联合替拉帕明和放疗的疗效：妇科肿瘤协作组研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2013.51.4265
DiSilvestro, Paul A; Ali, Shamshad; Craighead, Peter S; Lucci, Joseph A; Lee, Yi-Chun; Cohn, David E; Spirtos, Nicola M; Tewari, Krishnasu S; Muller, Carolyn; Gajewski, Walter H; Steinhoff, Margaret M; Monk, Bradley J
宫颈癌
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏